Home / Pharmaceutical company intelligence
Barrett Hodgson Pakistan (Pvt.) Ltd logo
Pharmaceutical company intelligence

Barrett Hodgson Pakistan (Pvt.) Ltd

Private pharmaceutical manufacturer · Karachi · Pakistan

Karachi-based pharmaceutical manufacturer with a broad branded portfolio and partnerships with international healthcare companies.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Barrett Hodgson Pakistan (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
F/423, S.I.T.E., Karachi-75700, Pakistan · 75700
Phone
+92 21 32570651-57
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000457 Barrett Hodgson Pakistan (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000457 188 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx188public portfolio records represented
REG161unique registrations represented
IDX187indexed MedInfoBase presentations
SRC1additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR187current validated price records
G63generic molecules in indexed catalogue
DF12dosage-form groups
TA12therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage99%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage89%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixBarrett Hodgson Pakistan (Pvt.) LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/barrett-hodgson-pakistan-pvt-ltdGenerated 25 Sep 2026Anti-infectives100 · 53%Cardiovascular28 · 15%CNS & mental health15 · 8%Respiratory & allergy11 · 6%Hematology & thrombosis7 · 4%Pain & musculoskeletal6 · 3%Anesthesia & critical care5 · 3%Other therapeutic areas15 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioBarrett Hodgson Pakistan (Pvt.) LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/barrett-hodgson-pakistan-pvt-ltdGenerated 25 Sep 2026187presentationsTablet83 · 44%Injection38 · 20%Suspension18 · 10%Capsule11 · 6%Cream10 · 5%Infusion10 · 5%Other forms17 · 9%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionBarrett Hodgson Pakistan (Pvt.) LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/barrett-hodgson-pakistan-pvt-ltdGenerated 25 Sep 2026167comparable productsBelow peer median75 · 45%Near peer median30 · 18%Above peer median62 · 37%Company median price position-0.2%Lowest-price equivalents33Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsBarrett Hodgson Pakistan (Pvt.) LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/barrett-hodgson-pakistan-pvt-ltdGenerated 25 Sep 2026Nabiqasim Industries (Pvt) Ltd.,40 shared63% overlapCCL Pharmaceuticals (Pvt.) Limited38 shared60% overlapBosch Pharmaceuticals (Pvt) Ltd.37 shared59% overlapM/s. Genix Pharma (Pvt) Ltd.36 shared57% overlapMediate Pharmaceutical Pvt Ltd36 shared57% overlapNovaMed Pharmaceuticals(Pvt.)Ltd35 shared56% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives100 products · 53%
Cardiovascular28 products · 15%
CNS & mental health15 products · 8%
Respiratory & allergy11 products · 6%
Hematology & thrombosis7 products · 4%
Pain & musculoskeletal6 products · 3%
Anesthesia & critical care5 products · 3%
Gastrointestinal & hepatology5 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins18 products · 10%
Fluoroquinolone antibacterials16 products · 9%
Antifungals12 products · 6%
Macrolide antibacterials12 products · 6%
Calcium-channel blockers11 products · 6%
Antivirals11 products · 6%
Antiepileptics10 products · 5%
Beta blockers7 products · 4%
Formulation footprint

Dosage forms

Tablet83 products
Injection38 products
Suspension18 products
Capsule11 products
Cream10 products
Infusion10 products
Solution6 products
Drops5 products
Inhalation2 products
Syrup2 products
Ointment1 products
Pessary1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 BarlevLevetiracetam 10presentations 100 mg/mL, 1000 mg, 250 mg, 500 mg · Solution, Tablet, Injection #2 InoquinCiprofloxacin 9presentations 100 mg/50 mL, 125 mg/5 mL, 200 mg, 200 mg/100 mL · Infusion, Suspension, Tablet #3 Telbar PlusTelmisartan + Amlodipine 9presentations 40 mg + 10 mg, 40 mg + 40 mg, 40 mg + 5 mg, 80 mg + 10 mg · Tablet #4 EntebarEntecavir 7presentations 0.5 mg, 1 mg · Tablet #5 InocefCeftriaxone 7presentations 1 g, 1000 mg, 2000 mg, 250 mg · Injection #6 MegaklarClarithromycin 7presentations 125 mg/5 mL, 250 mg, 250 MG/5 mL, 500 mg · Drops, Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median7545% of comparable products
Near market median30within ±5% of median
Above market median6237% of comparable products
Lowest-price equivalents33ties included
Company median price position -0.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Entebar 1 mgEntecavir · Tablet · 30's PKR 51.91/tablet-91.3% vs market median Entebar 1 mgEntecavir · Tablet · 10's PKR 56.56/tablet-90.5% vs market median Reform 50 mgSumatriptan · Tablet · 10's PKR 18.01/tablet-84.5% vs market median Silpor Silver 1 %Silver sulfadiazine · Cream · 500 gm PKR 0.80/g-78.9% vs market median Silpor Silver 1 %Silver sulfadiazine · Cream · 250 gm PKR 1.21/g-68.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 40shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 38shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 37shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 36shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 36shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 35shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers160Distinct registrations among indexed, published, presentation-validated products only
Verified price observations187
Products with a verified price187
Products with multiple price observations0
Source records with multiple versions186
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

161 unique registration(s) · 187 indexed presentation(s) · 1 additional source-observed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Adgam Eye Latanoprost 0.05 mg/mL Ophthalmic drops 2.5 ml 045472 PKR 577.76 PKR 231.10/mL 19% below median
Adgam-T Latanoprost + Timolol 0.05 mg/mL + 5 mg/mL Eye drops 2.5 ml 045473 PKR 1,501.53 PKR 600.61/mL No comparator
Ampress Amlodipine 10 mg Tablet 20's 024266 PKR 538.89 PKR 26.94/tablet 58% above median
Ampress Amlodipine 5 mg Tablet 20's 024365 PKR 275.49 PKR 13.77/tablet 27% above median
Bar-D Cholecalciferol 5 mg/mL (200,000 IU/mL) Injection 1's 083222 PKR 218.03 PKR 218.03/vial/unit Near median
Barforte Prednisolone 10 mg/mL Suspension 5ml 008629 PKR 150.77 PKR 30.15/mL 32% above median
Barigyl Metronidazole 200 mg Tablet 200's 095998 PKR 353.74 PKR 1.77/tablet 18% below median
Barigyl Metronidazole 400 mg Tablet 200's 095999 PKR 626.51 PKR 3.13/tablet 5% above median
Barigyl Metronidazole (Benzoate) 200 mg/5 mL Suspension 90ml 096000 PKR 87.20 PKR 0.97/mL Near median
Barigyl Metronidazole 500 mg/100 mL IV infusion 100ml 108742 PKR 110.19 PKR 1.10/mL 42% below median
Barilol Bisoprolol fumarate 2.5 mg Tablet 14's 075859 PKR 73.05 PKR 5.22/tablet 23% above median
Barilol Bisoprolol fumarate 5 mg Tablet 20's 075860 PKR 286.75 PKR 14.34/tablet 22% above median
Barilol Bisoprolol fumarate 10 mg Tablet 20's 075861 PKR 512.87 PKR 25.64/tablet 16% above median
Barilol-H Bisoprolol + Hydrochlorothiazide 2.5 mg + 6.25 mg Tablet 14's 086714 PKR 95.18 PKR 6.80/tablet 26% below median
Barilol-H Bisoprolol + Hydrochlorothiazide 2.5 mg + 6.25 mg Tablet 10's 086714 PKR 68.22 PKR 6.82/tablet 26% below median
Barilol-H Bisoprolol + Hydrochlorothiazide 5 mg + 6.25 mg Tablet 14's 086715 PKR 150.71 PKR 10.77/tablet 22% below median
Barilol-H Bisoprolol + Hydrochlorothiazide 10 mg + 6.25 mg Tablet 20's 086716 PKR 356.94 PKR 17.85/tablet 21% below median
Barimox Moxifloxacin 400 mg Tablet 5's 061443 PKR 994.59 PKR 198.92/tablet 9% above median
Baripenem Meropenem 500 mg Injection 1's 095252 PKR 1,806.40 PKR 1,806.40/vial/unit 13% below median
Baripenem Meropenem 1 g Injection 1's 095253 PKR 3,447.18 PKR 3,447.18/vial/unit 13% below median
Barizold Linezolid 600 mg Tablet 12's 076341 PKR 5,351.96 PKR 446.00/tablet 13% above median
Barizold Linezolid 400 mg Tablet 12's 076342 PKR 3,057.06 PKR 254.76/tablet 11% above median
Barizold Linezolid 100 mg/5 mL Dry suspension 60 ml 076343 PKR 712.13 PKR 11.87/mL 10% above median
Barizold Linezolid 200 mg/100 mL IV infusion 100 ml 076478 PKR 724.48 PKR 7.24/mL Near median
Barizold Linezolid 600 mg/300 mL IV infusion 300 ml 080288 PKR 1,231.67 PKR 4.11/mL 7% above median
Barizold Linezolid 400 mg/200 mL IV infusion 200 ml 080289 PKR 1,026.39 PKR 5.13/mL 22% above median
Barlev Levetiracetam 750 mg Tablet 30's 094919 PKR 2,896.70 PKR 96.56/tablet 26% below median
Barlev Levetiracetam 750 mg Tablet 10's 094919 PKR 965.57 PKR 96.56/tablet 26% below median
Barlev Levetiracetam 1000 mg Tablet 30's 094920 PKR 3,620.87 PKR 120.70/tablet 25% below median
Barlev Levetiracetam 1000 mg Tablet 10's 094920 PKR 1,206.96 PKR 120.70/tablet 25% below median
Barlev Levetiracetam 500 mg Tablet 10's 094921 PKR 855.06 PKR 85.51/tablet 10% below median
Barlev Levetiracetam 250 mg Tablet 10's 094922 PKR 515.00 PKR 51.50/tablet 7% below median
Barlev Levetiracetam 100 mg/mL Oral solution 60ml 094923 PKR 707.64 PKR 11.79/mL 13% below median
Barlev Levetiracetam 500 mg Extended-release tablet 10's 096001 PKR 939.58 PKR 93.96/tablet 16% below median
Barlev Levetiracetam 500 mg/5 mL Injection 5ml x 10's 108740 PKR 6,891.86 PKR 137.84/mL 8% above median
Barlev Levetiracetam 500 mg/5 mL Injection 5ml x 1's 108740 PKR 689.18 PKR 137.84/mL 8% above median
Barotrop 18mcg DPI Tiotropium 18 mcg Capsule 6's 086691 PKR 150.07 PKR 25.01/capsule 25% below median
Barotrop 18mcg DPI Tiotropium 18 mcg Capsule 15's 086691 PKR 367.68 PKR 24.51/capsule 26% below median
Barotrop 18mcg DPI Tiotropium 18 mcg Capsule 2x10's 086691 PKR 480.23 PKR 24.01/capsule 28% below median
Barotrop 18mcg DPI Tiotropium 18 mcg Capsule 3x10's 086691 PKR 720.34 PKR 24.01/capsule 28% below median
Barresten Clotrimazole 500 mg Vaginal tablet 1's 081446 PKR 130.32 PKR 130.32/tablet Near median
Barresten Clotrimazole 1% Cream 15gm 086692 PKR 69.03 PKR 4.60/g 20% below median
Barresten Clotrimazole 2% Cream 35gm 086693 PKR 105.05 PKR 3.00/g 32% below median
Barresten Clotrimazole 100 mg/g (10%) Vaginal cream 5gm 086694 PKR 139.71 PKR 27.94/g 16% below median
Barresten HC Clotrimazole + Hydrocortisone 1% + 1% w/w Cream 10 g 117945 PKR 118.09 PKR 11.81/g 13% below median
Barresten HC Clotrimazole + Hydrocortisone 10 mg/g + 10 mg/g Cream 30 g 117945 PKR 324.74 PKR 10.82/g 5% below median
Britanyl Terbutaline Terbutaline 0.5 mg/mL Injection 5’s amp 044256 PKR 125.32 PKR 25.06/vial/unit No comparator
Budecort-F Budesonide + Formoterol 200 mcg + 6 mcg Inhalation capsule 30's 085999 PKR 412.69 PKR 13.76/capsule 27% below median
Budecort-F Budesonide + Formoterol 100 mcg + 6 mcg Inhalation capsule 30's 086000 PKR 295.63 PKR 9.85/capsule 29% below median
Cefamezin Cefazolin 250 mg IV/IM injection 1's 008126 PKR 113.87 PKR 113.87/vial/unit No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Barrett Hodgson Pakistan (Pvt.) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/barrett-hodgson-pakistan-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.